Neurocrine Partners With Dainippon To Market Indiplon In Japan
This article was originally published in PharmAsia News
Dainippon Sumitomo will market Neurocrine Biosciences' insomnia agent indiplon in Japan under an exclusive liensing agreement announced Nov. 1
You may also be interested in...
Sleep aid could at last reach market late in 2008.
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).